Chiesi Farmaceutici S.p.a.

Genentech, Inc.

Corcept Therapeutics Incorporated

Ucl Biomedica Plc

F. Hoffmann-la Roche Ag

Christopher Hurley

Andrew Peter Cridland

Monique Bodil Van Niel

Elisabetta Armani

Nicholas Charles Ray

Lilian Alcaraz

Andrew Stephen Robert Jennings

Terry Aaron Panchal

Stuart Ward

Benjamin Fauber

Robin D Clark

Carmelida Capaldi

Karen Williams

Joseph P Lyssikatos

Emanuela Gancia

Bing-Yan Zhu

Hazel Joan Hunt

Jun Liang

Steven R Magnuson

David Edward Clark

Michael Siu

James John Crawford

Richard Pastor

Janusz Jozef Kulagowski

Peter Scott Dragovich

Hazel Joan Dyke

Wendy Lee

Sharada Shenvi Labadie

Mark Edward Zak

Srinivasan Babu

Emily J Hanan

Paul Gibbons

Rohan V Mendonca

Thomas E Rawson

Aihe Zhou

Jonathan Killen

Paul M Blaney

Alberto Gobbi

Paul Winship

Andrew Steven Robert Jennings

Olivier Rene

Sarah Bronner

Wendy Liu

He Haiying

Xiao Yisong

Zheng Jifu

Xu Xing

Zhao Junping

Jason R Zbieg

David Nigel Hurst

Stephen Lewis Hart

David Robert Vesey

Patrick Cyr

Bohdan Waszkowycz

Roberta Lanaro

Simon Gaines

Helen Claire Hailes

Tammy Ladduwahetty

Alethea Bernice Tabor

John Bosco Wong

Robert Maxey

Barbara Giuseppina Avitabile-Woo

Phillippe Bergeron

Stefan Gradl

Neil Stuart Jennings

Tony Johnson

Michael Koehler

Rebecca Pulk

Michael Pilkington-Miksa

Tammy Laddywahetty

Andrew Cridland

David Vesey

David Hurst

Compounds of formula I: or pharmaceutical salts thereof,wherein m, n, p, q A, B, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Pyridazine derivatives as RORc modulators

Compounds of formula I: or pharmaceutical salts thereof,wherein m, n, A, R1, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Compounds of formula (I) defined herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Kinase inhibitors

Compounds of formula I: or pharmaceutical salts thereof,

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X, X, X, X, Y, Z, A, R, R, R, R, RR, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

Aryl sultam derivatives as RORc modulators

Compounds of the formula I: or a pharmaceutical salt thereof,wherein X, Ar, R1, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Compounds of formulae (I), (II), and (III), defined herein, are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Mitogen activated protein kinase (MAPK) inhibitors disclosed herein are useful for the treatment of diseases of the respiratory tract, such as chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy, and airways disease that is associated with pulmonary hypertension.

Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38&#x2014;MAP kinase inhibitors

Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R, W, A, Y and Rare as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R, R, R, Rand Rare defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed. 

Triazolopyridine JAK inhibitor compounds and methods

Growing community of inventors

Harlow, United Kingdom

Christopher Hurley